arrow
B

Bram Boeckx

flanders institute for biotechnology (vib)
H指数:41
被引数:1.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Pan-cancer single-cell atlases of mouse and human tumor-associated dendritic cells

小鼠和人类肿瘤相关树突状细胞的泛癌单细胞图谱

2026-05-300
OAAI
Integrated multi-omics identifies distinct macrophage alterations during progression of metabolic dysfunction-associated steatohepatitis

整合多组学分析揭示代谢功能障碍相关脂肪性肝炎进展过程中巨噬细胞的特异性改变

2026-05-180
OAAI
Single-nucleus profiling reveals hepatocyte identity and immune features associated with corticosteroid response in severe alcohol-related hepatitis

单核分析揭示了严重酒精相关性肝炎中与皮质类固醇反应相关的肝细胞身份和免疫特征

2026-04-200
PRE
A pipeline of machine learning-driven multi-modal data fusion methods for prognostic risk analysis in bevacizumab-treated metastatic colorectal cancer

一种基于机器学习的多模态数据融合方法流程,用于贝伐珠单抗治疗转移性结直肠癌的预后风险分析

2026-04-010
OAAI
Expression of antibody-drug conjugate targets in post-mortem samples of breast cancer metastases and normal tissue

抗体偶联药物靶点在乳腺癌转移灶和正常组织死后样本中的表达

2025-12-260
OAAI
ctDNA detectability and representativeness in seven body liquids from patients with metastatic breast cancer

ctDNA在转移性乳腺癌患者七种体液中的检测性与代表性

2025-12-020
OAAI
Enhancing translational research in metastatic cancer through an open science environment: the UPTIDER experience

通过开放科学环境增强转移性癌症的转化研究:UPTIDER项目经验

2025-11-060
OAAI
Decoding tumor heterogeneity: A spatially informed pan-cancer analysis of the tumor microenvironment

解码肿瘤异质性:一项关于肿瘤微环境的基于空间信息的泛癌分析

2025-10-140
OAAI
Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial

新辅助nivolumab或nivolumab联合ipilimumab治疗早期三阴性乳腺癌: 2期适应性试验

2024-09-162
OAAI
A spatial architecture-embedding HLA signature to predict clinical response to immunotherapy in renal cell carcinoma ( vol 30 , pg 1667 , 2024)
2024-07-151
PRE
Single-cell RNA sequencing of cystic fibrosis liver disease explants reveals endothelial complement activation

囊性纤维化肝病外植体的单细胞RNA测序揭示了内皮补体激活

2024-06-073
PRE
A spatial architecture-embedding HLA signature to predict clinical response to immunotherapy in renal cell carcinoma
2024-05-217
PRE
Distinct immunometabolic signatures in circulating immune cells define disease outcome in acute-on-chronic liver failure
2024-05-162
OAAI
PI3K/mTOR inhibition induces tumour microenvironment remodelling and sensitises pS6high uterine leiomyosarcoma to PD-1 blockade
2024-05-062
OAAI
Rapid autopsies to enhance metastatic research: the UPTIDER post-mortem tissue donation program
2024-04-244
OAAI
Transcriptomic characterization of the histopathological growth patterns in breast cancer liver metastases

乳腺癌肝转移中组织病理学生长模式的转录组学特征

2024-03-290
OAAI
Heterogeneity of the hormone receptor-positive breast tumor immune microenvironment according to patient's body mass index

根据患者体重指数的激素受体阳性乳腺肿瘤免疫微环境的异质性

2024-03-220
PRE
Highly populated phylogenetic reconstruction in patients with hormone receptor positive-HER2 non-amplified metastatic breast cancer
2024-03-220
PRE
CD4+T cell activation distinguishes response to anti-PD-L1+anti-CTLA4 therapy from anti-PD-L1 monotherapy

CD4 T细胞活化区分对anti-PD-L1 anti-CTLA4疗法的反应与anti-PD-L1单一疗法

IMMUNITY
IF26.3
2024-03-0112
OAAI